Loss of FOXA1 Drives Sexually Dimorphic Changes in Urothelial Differentiation and Is an Independent Predictor of Poor Prognosis in Bladder Cancer
Opal L. Reddy(University of California, Los Angeles), David J. DeGraff(Penn State Milton S. Hershey Medical Center), Klaus H. Kaestner(Children's Hospital of Philadelphia), Henry Crist(Pennsylvania State University), Lan L. Gellert(Vanderbilt University Medical Center), Zhaohai Yang(University of Pennsylvania), Magdalena M. Grabowska(Vanderbilt University Medical Center), Michael S. Cookson(University of Oklahoma Health Sciences Center), Yajun Yi(Vanderbilt University), Xue‐Ru Wu(Chongqing Medical University), Hironobu Yamashita(Penn State Milton S. Hershey Medical Center), Daniel A. Barocas(Vanderbilt University Medical Center), Chaochen You(Vanderbilt University Medical Center), Peter E. Clark(Levine Cancer Institute), Robert J. Matusik(Vanderbilt University Medical Center), Fei Ye(University of Miami), Joseph A. Smith(King's College London), John A. Taylor(UConn Health), Sam S. Chang(Vanderbilt University), Justin Cates(Vanderbilt University Medical Center)
Cited by 71
Related Papers
The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia
|New England Journal of Medicine|2003|2k
Guideline for the Management of Clinically Localized Prostate Cancer: 2007 Update
|The Journal of Urology|2007|1.1k
Variation in the Definition of Biochemical Recurrence in Patients Treated for Localized Prostate Cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel Report and Recommendations for a Standard in the Reporting of Surgical Outcomes
|The Journal of Urology|2007|845